ABSI

Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.

Wall Street analysts forecast ABSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABSI is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Absci Corp revenue for the last quarter amounts to 378.00K USD, decreased -77.78 % YoY.

Absci Corp. EPS for the last quarter amounts to -0.20 USD, decreased -16.67 % YoY.

Absci Corp (ABSI) has 156 emplpoyees as of December 15 2025.

Today ABSI has the market capitalization of 509.76M USD.